EFS and OS of patients with extralymphatic craniofacial involvement treated without and with radiotherapy. There was no difference in EFS (A, left) and OS (B, right) between 145 patients with craniofacial involvement who received additive radiotherapy and 57 patients who did not. A similar picture emerged from the analysis of patients treated without rituximab (B: 107 patients who received radiotherapy, 41 patients who did not) and with rituximab (C: 38 patients who received radiotherapy, 16 patients who did not). Gray dashed curves represent patients who received and black curves represent patients who did not receive radiotherapy.